PharmacovigilanceOfficial
EMA publishes PSUSA outcome for nationally authorised split-virion inactivated influenza vaccines, recommending a variation
🇪🇺 EMA · Fri 20 Nov 2026
The EMA has published the single assessment of safety update reports for non-centrally authorised split-virion inactivated influenza vaccines, with the regulatory outcome listed as a variation.
The European Medicines Agency published the outcome of procedure PSUSA/00010298/202603 on 20 November 2026. The procedure covers influenza vaccine (split virion, inactivated) in products that are not centrally authorised, meaning those approved at national level.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Article written by VigiEye from the official source (EMA). AI-assisted; check the source before acting.
More Pharmacovigilance
All →
FDA early alert: Heraeus Medevio recalls vascular guidewires over hydrophilic coating clumping risk
🇺🇸 FDA MedWatch · Fri 20 Nov 2026
EMA publishes PSUSA outcome for ibuprofen medicines, concluding with a variation
🇪🇺 EMA · Fri 20 Nov 2026
CMS proposes Medicare Advantage rule to ease market entry and widen beneficiary choice
🇺🇸 CMS · Fri 20 Nov 2026
CMS issues proposed rule on 2028 Medicare Advantage and Part D changes
🇺🇸 CMS · Fri 20 Nov 2026
FDA warns Florida clinical investigator over consent failings in INSTI HIV self-test study
🇺🇸 FDA CBER · Fri 20 Nov 2026
Breckenridge recalls one lot of propranolol ER 60 mg capsules over possible metal contamination
🇺🇸 FDA MedWatch · Fri 20 Nov 2026